Aaron Wealth Advisors LLC Grows Stake in Johnson & Johnson (NYSE:JNJ)

Aaron Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,189 shares of the company’s stock after buying an additional 1,420 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Joule Financial LLC raised its holdings in shares of Johnson & Johnson by 8.0% in the third quarter. Joule Financial LLC now owns 2,324 shares of the company’s stock worth $377,000 after buying an additional 173 shares during the last quarter. Stonegate Investment Group LLC raised its stake in Johnson & Johnson by 0.6% in the 3rd quarter. Stonegate Investment Group LLC now owns 540,579 shares of the company’s stock worth $87,606,000 after acquiring an additional 3,438 shares during the last quarter. Sloy Dahl & Holst LLC raised its stake in shares of Johnson & Johnson by 7.0% in the third quarter. Sloy Dahl & Holst LLC now owns 5,794 shares of the company’s stock worth $939,000 after purchasing an additional 380 shares during the last quarter. V Square Quantitative Management LLC lifted its holdings in shares of Johnson & Johnson by 7.9% during the third quarter. V Square Quantitative Management LLC now owns 45,541 shares of the company’s stock worth $7,380,000 after purchasing an additional 3,320 shares during the period. Finally, CHB Investment Group LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth approximately $594,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. TD Securities reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. The Goldman Sachs Group reduced their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. TD Cowen lowered their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Finally, Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.4 %

Shares of JNJ stock opened at $165.13 on Friday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The firm has a market capitalization of $397.41 billion, a P/E ratio of 10.29, a PEG ratio of 2.65 and a beta of 0.52. The stock’s fifty day moving average is $162.98 and its two-hundred day moving average is $154.71. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.66 EPS. Research analysts expect that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.